Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baiziqian Lifei Zhike Granules is a Traditional Chinese Medicine (TCM) formulation developed by Weihai Dishang Bioproducts (a subsidiary of Dishang Group) for the treatment of acute tracheobronchitis. The product is designed to alleviate symptoms such as cough and phlegm associated with acute respiratory tract inflammation. The name 'Baiziqian' suggests a composition likely including *Stemona* (Baibu), *Aster tataricus* (Ziwan), and *Peucedanum praeruptorum* (Qianhu), which are traditional TCM herbs used to moisten the lungs, resolve phlegm, and suppress cough. It has been evaluated in clinical trials in China (e.g., CTR20150308) to assess its efficacy and safety compared to placebo in patients with acute tracheobronchitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baiziqian Lifei Zhike Granules.